Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From May 2019 to May 2024
TKT To Report Third Quarter Financial Results On November 9, 2004
CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) will report third quarter 2004 financial results on Tuesday,
November 9, 2004 before the open of U.S. financial markets. In connection with
this announcement, TKT will host a conference call and live audio webcast on
November 9, 2004 at 10:00 a.m. Eastern Time. Participants may access the call
by dialing (719) 457-2618. This call will also be broadcast live over the
Internet at http://www.tktx.com/ under the Investor Information section.
A replay of this conference call will be available for two weeks, beginning
Tuesday, November 9, 2004 at 1:00 p.m. Eastern Time by dialing (719) 457-0820
and using the access code 953576. In addition, a replay of the webcast will be
archived on the TKT website in the Investor Information section.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused
on researching, developing and commercializing treatments for rare diseases
caused by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. Outside its
focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com/.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
CONTACT:
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/
DATASOURCE: Transkaryotic Therapies, Inc.
CONTACT: Daniella M. Lutz, Corporate Communications Manager of
Transkaryotic Therapies, Inc., +1-617-349-0205
Web site: http://www.tktx.com/
Company News On-Call: http://www.prnewswire.com/comp/120657.html